162 related articles for article (PubMed ID: 33288484)
1. The Burden in Caregivers of Multiple Myeloma Patients Undergoing Outpatient Autologous Stem-Cell Transplantation Compared to Inpatient Transplantation.
Martino M; Pitino A; Tripepi G; Paviglianiti A; Russo L; Cusumano G; Rossetti A; Provenzano PF; Porto G; Meliambro N; Gallo S; Porcino D; Romeo V; Gangemi T; D'Arrigo G; Imbalzano L; Console G; Gori M
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e402-e409. PubMed ID: 33288484
[TBL] [Abstract][Full Text] [Related]
2. Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis.
Owattanapanich W; Suphadirekkul K; Kunacheewa C; Ungprasert P; Prayongratana K
BMC Cancer; 2018 Nov; 18(1):1126. PubMed ID: 30445930
[TBL] [Abstract][Full Text] [Related]
3. A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model.
Martino M; Ciavarella S; De Summa S; Russo L; Meliambro N; Imbalzano L; Gallo GA; Moscato T; Messina G; Ferreri A; Cuzzola M; Irrera G; Naso V; Cimminiello M; Console G; Loseto G; Tommasi S; Guarini A
Biol Blood Marrow Transplant; 2018 Mar; 24(3):608-613. PubMed ID: 29032271
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation.
Obiozor C; Subramaniam DP; Divine C; Shune L; Singh AK; Lin TL; Abhyankar S; Chen GJ; McGuirk J; Ganguly S
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1641-1645. PubMed ID: 28603071
[TBL] [Abstract][Full Text] [Related]
5. A comparison of inpatient and outpatient ASCT.
Summers N; Dawe U; Stewart DA
Bone Marrow Transplant; 2000 Aug; 26(4):389-95. PubMed ID: 10982285
[TBL] [Abstract][Full Text] [Related]
6. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.
Naumann-Winter F; Greb A; Borchmann P; Bohlius J; Engert A; Schnell R
Cochrane Database Syst Rev; 2012 Oct; 10():CD004626. PubMed ID: 23076906
[TBL] [Abstract][Full Text] [Related]
7. Advances in delivery of ambulatory autologous stem cell transplantation for multiple myeloma.
Khouri J; Majhail NS
Curr Opin Support Palliat Care; 2017 Dec; 11(4):361-365. PubMed ID: 28922292
[TBL] [Abstract][Full Text] [Related]
8. Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes.
Ebraheem MS; Seow H; Balitsky AK; Pond GR; Wildes TM; Sivapathasundaram B; Sussman J; Mian H
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e714-e721. PubMed ID: 34099429
[TBL] [Abstract][Full Text] [Related]
9. Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center.
Kodad SG; Sutherland H; Limvorapitak W; Abou Mourad Y; Barnett MJ; Forrest D; Gerrie A; Hogge DE; Nantel SH; Narayanan S; Nevill T; Power M; Sanford D; Toze C; White J; Broady R; Song K
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):784-790. PubMed ID: 31678079
[TBL] [Abstract][Full Text] [Related]
10. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.
Garderet L; Iacobelli S; Koster L; Goldschmidt H; Johansson JE; Bourhis JH; Krejci M; Leleu X; Potter M; Blaise D; Koenecke C; Peschel C; Radocha J; Metzner B; Lenain P; Schäfer-Eckart K; Pohlreich D; Grasso M; Caillot D; Einsele H; Ladetto M; Schönland S; Kröger N
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1372-1378. PubMed ID: 29408334
[TBL] [Abstract][Full Text] [Related]
11. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
12. Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma.
Paul TM; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Nasta SD; Loren A; Frey N; Perl A; Cohen AD; Weiss BM; Stadtmauer EA; Vogl DT
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):536-40. PubMed ID: 26141214
[TBL] [Abstract][Full Text] [Related]
13. Safety and survival outcomes for bloodless transplantation in patients with myeloma.
Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR; Graiser M; Heffner LT; Lonial S; Nooka AK
Cancer; 2019 Jan; 125(2):185-193. PubMed ID: 30480777
[TBL] [Abstract][Full Text] [Related]
14. Pilot Trial of Homebound Hematopoietic Cell Transplantation.
Landau HJ; Orlando E; Rodriguez ES; Applebaum A; Mitchell HR; Peled JU; Khan N; Funnell T; Chung D; Scordo M; Shah GL; LeStrange NJ; Hambright KA; McElrath CM; Cazeau N; Devlin SM; Perales MA; Giralt SA
Transplant Cell Ther; 2022 Dec; 28(12):832.e1-832.e7. PubMed ID: 36182105
[TBL] [Abstract][Full Text] [Related]
15. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
Katragadda L; McCullough LM; Dai Y; Hsu J; Byrne M; Hiemenz J; May S; Cogle CR; Norkin M; Brown RA; Wingard JR; Chang M; Moreb JS
Clin Transplant; 2016 Aug; 30(8):894-900. PubMed ID: 27219740
[TBL] [Abstract][Full Text] [Related]
16. Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation.
Mohyuddin GR; Abbasi S; Okoniewski M; McClune B; Abdallah AO; Ganguly S; McGuirk J; Shune L
Eur J Haematol; 2020 Nov; 105(5):571-577. PubMed ID: 32662224
[TBL] [Abstract][Full Text] [Related]
17. Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.
Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Bone Marrow Transplant; 2018 Feb; 53(2):155-161. PubMed ID: 29131152
[TBL] [Abstract][Full Text] [Related]
18. Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.
Martino M; Lemoli RM; Girmenia C; Castagna L; Bruno B; Cavallo F; Offidani M; Scortechini I; Montanari M; Milone G; Postacchini L; Olivieri A
Bone Marrow Transplant; 2016 Aug; 51(8):1032-40. PubMed ID: 27042841
[TBL] [Abstract][Full Text] [Related]
19. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
20. Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma.
Holbro A; Ahmad I; Cohen S; Roy J; Lachance S; Chagnon M; LeBlanc R; Bernard L; Busque L; Roy DC; Sauvageau G; Kiss TL
Biol Blood Marrow Transplant; 2013 Apr; 19(4):547-51. PubMed ID: 23253556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
